BIO-TECHNE Corp — Director's Dealing 2021

Aug 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-08-23

Reporting Person: BAUMGARTNER ROBERT V (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-23	Common Stock	M	4000	$87.39	Acquired	13612	Direct
2021-08-23	Common Stock	S	299	$481.774	Disposed	13313	Direct
2021-08-23	Common Stock	S	601	$483.5993	Disposed	12712	Direct
2021-08-23	Common Stock	S	600	$485.0254	Disposed	12112	Direct
2021-08-23	Common Stock	S	1600	$486.2526	Disposed	10512	Direct
2021-08-23	Common Stock	S	800	$487.1027	Disposed	9712	Direct
2021-08-23	Common Stock	S	100	$487.8823	Disposed	9612	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-23	Stock Options (right to buy)	$87.39	M	4000	Disposed	2023-10-30	Common Stock (4000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (right to buy)	$91.78	2024-10-30	Common Stock (4000)	4000	Direct
Stock Options (right to buy)	$87.34	2025-10-28	Common Stock (4260)	4260	Direct
Stock Options (right to buy)	$101.19	2026-10-26	Common Stock (3985)	3985	Direct
Stock Options (right to buy)	$125.05	2027-10-26	Common Stock (3125)	3125	Direct
Stock Options (right to buy)	$179.84	2028-10-25	Common Stock (1898)	1898	Direct
Stock Options (right to buy)	$201.64	2029-10-24	Common Stock (2011)	2011	Direct
Stock Options (right to buy)	$255.69	2030-10-29	Common Stock (1507)	1507	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.41 to $482.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.01 to $483.86, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.52 to $485.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.59 to $486.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.84 to $487.52, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.87 to $487.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The option vests on the earlier of the one year anniversary of the grant date (10/29/20) or the date of Bio-Techne's 2021 annual meeting of shareholders.